Homare Eda
YOU?
Author Swipe
View article: Supplementary Figure 1 from Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma
Supplementary Figure 1 from Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma Open
Supplementary Figure 1: U266 cells were transiently transfected with 500 nM of small interfering RNA (siRNA) SMARTpool for IGF1R or nonspecific control duplexes (pool of four; Thermo Scientific Dharmacon) using the Cell Line Nucleofector K…
View article: Data from Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma
Data from Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma Open
Despite promising preclinical results with mTOR kinase inhibitors in multiple myeloma, resistance to these drugs may arise via feedback activation loops. This concern is especially true for insulin-like growth factor 1 receptor (IGF1R), be…
View article: Supplementary Figure 1 from Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma
Supplementary Figure 1 from Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma Open
Supplementary Figure 1: U266 cells were transiently transfected with 500 nM of small interfering RNA (siRNA) SMARTpool for IGF1R or nonspecific control duplexes (pool of four; Thermo Scientific Dharmacon) using the Cell Line Nucleofector K…
View article: Data from Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma
Data from Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma Open
Despite promising preclinical results with mTOR kinase inhibitors in multiple myeloma, resistance to these drugs may arise via feedback activation loops. This concern is especially true for insulin-like growth factor 1 receptor (IGF1R), be…
View article: <scp>TRACP</scp> ‐ <scp>5b</scp> / <scp>BAP</scp> Score After 3 Months of Treatment With Combined <scp>SERM</scp> / <scp>E2</scp> Therapy Can Predict Changes in Lumbar Spine Bone Mineral Density After 1 Year of Treatment in Early Postmenopausal Osteopenia
<span>TRACP</span> ‐ <span>5b</span> / <span>BAP</span> Score After 3 Months of Treatment With Combined <span>SERM</span> / <span>E2</span> Therapy Can Predict Changes in Lumbar Spine Bone Mineral Density After 1 Year of Treatment in Early Postmenopausal Osteopenia Open
Although changes in bone mineral density (BMD) are important indexes in osteoporosis treatment, no markers are available to predict them. Given the importance of assessing the therapeutic windows of antiresorptives, we explored potential b…
View article: Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy
Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy Open
Regulation of STAT3 activation is critical for normal and malignant hematopoietic cell proliferation. Here, we have reported that the endogenous transmembrane protein upstream-of-mTORC2 (UT2) negatively regulates activation of STAT3. Speci…
View article: Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease
Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease Open
Sclerostin is a potent inhibitor of osteoblastogenesis. Interestingly, newly diagnosed multiple myeloma (MM) patients have high levels of circulating sclerostin that correlate with disease stage and fractures. However, the source and impac…